

- **Name:** Hee Kyung Ahn
 - **Current Position & Affiliation:** Clinical Professor
Division of Hematology-Oncology
Department of Medicine
Samsung Medical Center
 - **Country:** Korea
-

• Educational Background:

2023	PhD	Sungkyunkwan University, School of Medicine, Seoul, Korea (Internal Medicine)
2012	MS	Sungkyunkwan University, School of Medicine, Seoul, Korea (Internal Medicine)
2005	MD	Sungkyunkwan University, School of Medicine, Seoul, Korea (Medicine)

• Professional Experience:

Mar 2024-Present	Clinical professor, Division of Hematology-Oncology Samsung Medical Center, Seoul, Korea
Sep 2024-Feb 2024	Clinical associate professor, Division of Hematology-Oncology Samsung Medical Center, Seoul, Korea
Mar 2024-Aug 2024	Professor, Division of Medical Oncology Gachon University Gil Medical Center, Incheon, Korea
Mar 2019-Feb 2024	Associate professor, Division of Medical Oncology Gachon University Gil Medical Center, Incheon, Korea
Mar 2013-Feb 2019	Assistant professor, Division of Medical Oncology Gachon University Gil Medical Center, Incheon, Korea
Mar 2012-Feb 2013	Clinical assistant professor, Division of Hematology and Oncology Gachon University Gil Medical Center, Incheon, Korea
Mar 2010-Feb 2012	Clinical fellow, Division of Hematology-Oncology, Department of Medicine Samsung Medical Center, Seoul, Korea
Mar 2006-Feb 2010	Resident, Department of Medicine, Samsung Medical Center, Seoul, Korea
Mar 2005-Feb 2006	Intern, Samsung Medical Center, Seoul, Korea

• Professional Organizations:

Member of Korean Society of Medical Oncology(KSMO), Korean Cancer Study Group(KSCG), Korean Breast Cancer Society(KBCS), Korean Society for Hospice and Palliative care, European Society of Medical Oncology(ESMO), and American Society of Clinical Oncology(ASCO).

Jun 2023-May 2025, Chair of the 11th Korean Clinical Practice Guideline for Breast Cancer, KBCS

May 2020- May 2024, Secretary of International Affairs Committee, KSMO

Sep 2019- Feb 2023, Secretary of Breast Cancer Committee, KCSG

• Main Scientific Publications:

1. **Ahn HK**, Kim JY, Lee KH, Kim GM, Kang SY, Lee KS, Kim JH, Lee KE, Lee MH, Kim HJ, Kim HJ, Koh SJ, Park IH, Sohn J, Kim SB, Ahn JS, Kim S, Cho H, Jung KH, Im SA, Park YH; Korean Cancer Study Group (KCSG) Breast Cancer Committee. Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study. **Lancet Oncol.** 2025 Mar;26(3):343-354. doi: 10.1016/S1470-2045(25)00006-3. Epub 2025 Feb 17.
2. Hong MH, Choi YJ, **Ahn HK**, Keam B, Kim D-W, Kim TM, Youk J, Kim YJ, Hwang S, Kim S, Kim JW, Kim HR, Kang JH. Lazertinib in EGFR-mutant non-small cell lung cancer with CNS failure to prior EGFR-TKI. **JAMA oncol.** 2024 Aug 15:e242640. doi: 10.1001/jamaoncol.2024.2640. Online ahead of print.
3. **Ahn HK**, Sim SH, Suh KJ, Kim MH, Jeong JH, Kim JY, Lee DW, Ahn JH, Chae H, Lee KH, Kim JH, Lee KS, Sohn JH, Choi YL, Im SA, Jung KH, Park YH. Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial. **JAMA Oncol.** 2022 Sep 1;8(9):1271-1277. doi: 10.1001/jamaoncol.2022.2310.